RVMD Q3 2025 Earnings
Reported Nov 5, 2025 at 4:00 PM ET · SEC Source
Q3 25 EPS
$-1.61
MISS 14.25%
Est. $-1.41
Q3 25 Revenue
N/A
Est. $1.6M
vs S&P Since Q3 25
+123.5%
BEATING MARKET
RVMD +131.0% vs S&P +7.5%
Market Reaction
Did RVMD Beat Earnings? Q3 2025 Results
Revolution Medicines delivered a steeper-than-expected loss in Q3 2025, missing Wall Street estimates as the clinical-stage oncology company accelerates spending across its RAS(ON) inhibitor pipeline. The company posted a loss of $1.61 per share, fal… Read more Revolution Medicines delivered a steeper-than-expected loss in Q3 2025, missing Wall Street estimates as the clinical-stage oncology company accelerates spending across its RAS(ON) inhibitor pipeline. The company posted a loss of $1.61 per share, falling short of the $-1.41 consensus by 14.25%, with no product revenue given its pre-commercial status. The primary driver was a near-doubling of R&D expenses to $262.51 million, reflecting expanded late-stage trial activity and manufacturing costs for daraxonrasib, zoldonrasib, and elironrasib, while G&A expenses more than doubled to $52.76 million as the company builds out commercial infrastructure. The net loss widened to $305.21 million from $156.29 million a year ago. Despite the shortfall, Revolution Medicines maintained full-year 2025 net loss guidance of $1.03 billion to $1.09 billion and enters 2026 with $1.93 billion in liquidity, key data readouts expected from the RASolute 302 trial, and plans to initiate a registrational zoldonrasib combination study in first-line PDAC in the first half of next year.
Key Takeaways
- • Increased R&D spending driven by expanded clinical trial activity and manufacturing for daraxonrasib, zoldonrasib, and elironrasib
- • Higher G&A expenses from commercial preparation activities and headcount growth
- • Royalty Pharma partnership providing capital with $250 million first tranche received in June 2025
RVMD YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
“Our diverse clinical and preclinical RAS(ON) inhibitor programs continue to make encouraging progress and deliver on important milestones. Backed by robust operational capabilities and a strong financial position, we feel growing momentum in support of our goal to establish new global standards of care for people living with RAS-addicted cancers, including pancreatic, lung and colorectal cancers.”
— Mark A. Goldsmith, Q3 2025 Earnings Press Release
RVMD Earnings Trends
RVMD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RVMD EPS Trend
Earnings per share: estimate vs actual
RVMD Revenue Trend
Quarterly revenue: estimate vs actual
RVMD Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $-1.58 | $-1.86 | -17.72% | — | — |
| FY Full Year | $-5.53 | $-5.95 | -7.53% | — | — |
| Q3 25 MISS | $-1.41 | $-1.61 | -14.25% | — | — |
| Q2 25 MISS | $-1.12 | $-1.31 | -16.75% | — | — |
| Q1 25 MISS | $-1.06 | $-1.13 | -7.02% | — | — |